{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle (C) 5- Hypertension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"C5 - Renal failure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"C5 - Weight increased"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"}],"units":"Participants"}],"groups":[{"description":"Participants were enrolled in an induction phase and received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone \\[CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone \\[CVP - 21-day cycle\\]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator was free to choose the chemotherapy for each participant.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"The safety population included all participants who received at least one dose of obinutuzumab. Only 1 participant had a Grade \\>=3 IRR, with 3 symptoms in Cycle 5. Weight increased was a grade 1 symptom belonging to the grade 3 IRRs.","reportingStatus":"POSTED","timeFrame":"All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)","title":"Type of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}